Undisclosed RIPK1 inhibitor / Rigel Pharmaceuticals - LARVOL DELTA

Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor. (PubMed, Clin Transl Sci) - "Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis...In a phase 1, double-blind, randomized, multiple-dose study in healthy participants, greater than 90% RIPK1 target engagement was achieved at Day 14 with ocadusertib treatment. Taken together, these findings support further assessment of ocadusertib for the treatment of chronic inflammatory diseases."

First-in-human • Journal • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Rheumatoid Arthritis • Rheumatology • CDK7 • RIPK1 • TNFA

Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor (ACR Convergence 2024) - "Ocadusertib (LY3871801; R552) is a potent and selective allosteric inhibitor of RIPK1 that blocks inflammatory cell death and is currently being studied in clinical trials. Preclinical studies have demonstrated ocadusertib to be a potent and selective allosteric inhibitor of RIPK1 inhibitor. In a Phase 1 study, ocadusertib had a long t1/2, was well tolerated, and had an acceptable safety profile. These findings support further assessment of ocadusertib in chronic inflammatory diseases including rheumatoid arthritis."

Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Rheumatoid Arthritis • Rheumatology • CDK7 • RIPK1